NEW YORK, NY / ACCESSWIRE / February 14, 2018 / Strong performances from banking and technology stocks helped lift the markets further into the green on Tuesday. The Dow Jones Industrial Average gained 0.16 percent to close at 24,640.45, while the S&P 500 Index increased 0.26 percent to close at 2,662.94. The tech-heavy Nasdaq Composite Index rose 0.45 percent to close at 7,013.51. U.S. markets have experienced steep declines last week on rising interest rates and inflation concerns.
"If inflation continues to pick up, the equity market will continue to struggle from here. If worries about inflation come true, the problem is that central banks will have no choice but to raise rates, which won't just have an impact on the equity markets but also on the real economy," said Nick Clay, the lead manager of the BNY Mellon Global Equity Higher Income Fund, according to MarketWatch.
RDI Initiates Coverage on:
Catabasis Pharmaceuticals, Inc.
ImmunoCellular Therapeutics, Ltd.
Catabasis Pharmaceuticals' stock jumped 24.80% Tuesday, to close the day at $1.56. The stock recorded a trading volume of 26,995,273 shares, which was above its three months average volume of 217,758 shares. In the last year, Catabasis Pharmaceuticals' shares have traded in a range of 1.09 - 3.78. The share price has gained 43.12% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $1.48 is below its 200-day moving average of $1.69. Shares of Catabasis Pharmaceuticals have gained roughly 1.3 percent in the past month and are up 4.7 percent year-to-date.
Access RDI's Catabasis Pharmaceuticals, Inc. Research Report at:
On Tuesday, shares of ImmunoCellular Therapeutics recorded a trading volume of 5,131,067 shares, which was above the three months average volume of 2,761,088 shares. The stock ended the day 14.58% higher at 0.26. The share price has gained 53.00% from its 52 week low with a 52 week trading range of 0.17 - 3.68. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.29 is below its 200-day moving average of $0.32. Shares of ImmunoCellular Therapeutics have fallen roughly 16.07 percent in the past month and are down 17.72 percent year-to-date.
Access RDI's ImmunoCellular Therapeutics, Ltd. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.